The NEOMED Institute is a response to the changing pharma R&D business model. In view of the considerable gap between basic research and the commercialization of new drugs, we seek to create a bridge.
We provide industrial expertise in drug discovery and development combined with funding and a favourable ecosystem to transform innovations into solid therapeutic solutions. We drive drug discovery activities up to the stage of human proof of concept. This stage is an important turning point, where projects become attractive to the biopharmaceutical industry or can constitute the basis for the creation of solid start-up companies.
We have two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, is located in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
Our overall focus is to create and maximize value for promising therapeutic approaches originating from academic labs or biotechnology companies. We provide competent drug discovery and development expertise combined with financing, from target to clinical proof of concept.
Our model is flexible. Projects can enter or exit the pipeline at various stages of development. They are led according to industry standards, lowering execution risk and maximizing value creation and the chances of commercial success. At predetermined development stages, the projects are out-licensed to pharma partners for further development or they serve to generate new companies around solid assets.
Scout for new projects by interacting closely with academic labs, biotechnology companies, technology transfer offices, and other valorization structures interested in therapeutic innovation, particularly in the discovery of novel medication for innovative targets.
Reinvest the benefits from the out-licensing in our R&D fund to support new projects and thus returning value to our partners and the community.
Define the optimal development strategy for each new project with the help of our dedicated drug discovery and development experts and our international Scientific Advisory Board.
Implement the agreed strategy to reach key milestones where the project can be out-licensed or used to create start-up companies. Project activities are outsourced and conducted in the relevant contract research organizations (CROs) within our facilities in Saint-Laurent or Laval, or elsewhere.
Outstanding research and development facilities in Saint-Laurent and Laval acting as open-access drug discovery hubs, where all the players in the life sciences ecosystem interface and network to discover the drugs of tomorrow. Contract research organizations (CROs), biotechnology companies, start-ups, and intellectual property specialists are co-located to facilitate translational research and to foster collaboration, innovation, and creativity.